To explore the disease outcome prognosis of cough variant asthma by observing the outcomes of cough variant asthma and the effects of Chinese and Western medicine interventions, and to provide a scientific basis for optimizing the treatment protocol of combined traditional and Western medicine for cough variant asthma. This is a multi-center, non-randomized, prospective cohort study. This study started in March 2022 and is going on now. On an informed consent basis, a cohort of 164 patients with diagnosis of CVA are engaged. All patients will receive 8-week treatment (ICS/LABA plus Chinese herbal medicine for trial group while ICS/LABA only for control group) and be observed in next 24 weeks. Patients will be followed up every 2 weeks during treatment period and every 4 weeks in observation.The feasibility and correctness of the study will be supervised by two supervisors. To ensure that participants adhere to their follow-up plans, we remind them of their fixed visiting by phone or message. Additionally, incentives are used to appreciate participants for their cooperation.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
164
200ml, bid, for 8 weeks
one suction, q12h, for 8 weeks
Hangzhou Hospital of Traditional Chinese Medicine
Hangzhou, China
NOT_YET_RECRUITINGThe First Affiliated Hospital of Zhejiang Chinese Medical University
Hangzhou, China
RECRUITINGXin Hua Hospital of Zhejiang Province
Hangzhou, China
NOT_YET_RECRUITINGThe First People's Hospital of Wenling
Taizhou, China
NOT_YET_RECRUITINGtotal effective rate calculated by the Cough-related Symptom Scale
Cough-related Symptom Scale is specially designed for this trial. Question1-5 in CSS comes from Chinese national guideline on diagnosis and management of cough (2021) and the rest questions are set based on clinical experience and other study . Total effective rate can be directly reflected in Efficacy Index (EI) which set by National Medical Products Administration .
Time frame: week 8
total effective rate calculated by the Cough-related Symptom Scale
Cough-related Symptom Scale is specially designed for this trial. Question1-5 in CSS comes from Chinese national guideline on diagnosis and management of cough (2021) and the rest questions are set based on clinical experience and other study . Total effective rate can be directly reflected in Efficacy Index (EI) which set by National Medical Products Administration .
Time frame: week 32
change from baseline in Cough-related Symptom Scale
This scale consists of two parts. Question1-5 come from Chinese national guideline on diagnosis and management of cough (2021) to evaluate the symptom of cough. Question6-10 are some accompanying performances, including cough-stimulated factors like wind, cold air, smoking etc, sputum, sensations of "persistent tickling", "thirsty", "Qi inversion" in throat.
Time frame: baseline and week 8 ,baseline and week 32
change from baseline in Cough severity visual analogue scale
Cough severity visual analogue scale (VAS) is used to record participants' assessments of cough severity. It is shown as a 0-mm to 100-mm liner scale ranging from "no cough" to "severe cough". The bigger score represents more severe cough.
Time frame: baseline and week 8 ,baseline and week 32
change from baseline in Leicester Cough Questionnaire
Leicester Cough Questionnaire, as a useful tool in clinical trial, consists of 19 items which is a repeatable, valid self-evaluated quality of life measure of chronic cough and responsive to change .
Time frame: baseline and week 8 ,baseline and week 32
change from baseline in Pulmonary function
Pulmonary function test reveals some details of a patient's condition in respiratory function, like forced vital capacity (FVC), forced expiratory volume in one second (FEV1), FEV1/FVC, peak expiratory flow (PEF), forced expiratory flow 25% (FEF25), forced expiratory flow 75% (FEF75), forced expiratory flow between 25% and 75% of forced vital capacity (FEF(25-75)) etc.
Time frame: baseline and week 8 ,baseline and week 32
CVA recurrence rate from week 8 to week 32
CVA recurrence rate is defined as the occurance rate of similar cough which conforms to CVA diagnosis criteria during 6-month observation.
Time frame: week 32
the ratio of progressing to typical asthma from week 8 to week 32
the ratio of progressing to typical asthma is characterized as the ratio of participants who turning from CVA into classic asthma based on Guidelines for bronchial asthma prevent and management (2020 edition) during 6-month observation.
Time frame: week 32
change from baseline in fractional exhaled nitric oxide
Nitric oxide (NO) is produced by inducible nitric oxide synthase (iNOS) in airway epithelial cells and FENO is associated with eosinophilic airway inflammation which usually indicates the sensitivity to ICS.
Time frame: baseline and week 8 ,baseline and week 32
change from baseline in Serum IgE
IgE is linked to its ability to affect several immune and structural cells involved in allergic asthma.
Time frame: baseline and week 8 ,baseline and week 32
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.